Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1358894 in PTSD
NCT05103657Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of bi 1358894 in post-traumatic stress disorder (PTSD), sponsored by Boehringer Ingelheim. Started Dec 2021; status: completed.
02
Drugs
bi 1358894
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05103657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103657.